Free Newsletter
ALSO NOTED: Sanofi sues to fight off Uroxatral imitators; Watson gets OK for generic AccuNeb
> Sanofi Aventis sued two generics makers--Teva Pharmaceuticals and Barr Laboratories--for infringing its patents on the prostate cancer drug Uroxatral. Report
> Watson Pharmaceuticals got the FDA nod for its generic form of the asthma medication AccuNeb. Report
> Sanofi Pasteur is scouting India, among other countries, for possible locations for a global manufacturing base, the Economic Times reports. Report
> AstraZeneca is poised to open an Israeli office and is seeking a local general manager there. Report
And Finally... Don't count on snagging your daily meds from a pharma facility. The thieves who got out of Genentech with human growth hormone are exceptions to the high-security rule--so much so that one expert likened a drug-company theft to stealing gold from Fort Knox. Report
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage


